Patents Assigned to 1149336 Ontario Inc.
  • Methods of regulating glucose metabolism, and reagents related thereto
    Patent number: 9044424
    Abstract: The present invention provides methods for modification and regulation of glucose metabolism by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to increase the plasma half-life of glucagon-like peptide 1 (GLP-1) but not sufficient to suppress the immune system of the animal.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: June 2, 2015
    Assignees: 1149336 Ontario, Inc., New England Medical Center Hospitals. Inc., Trustees of Tufts College
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
  • Glucagon-like peptide-2 analogs
    Patent number: 8933039
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: January 13, 2015
    Assignees: NPS Pharmaceuticals, Inc., 1149336 Ontario Inc.
    Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Glucagon-like peptide-2 analogs
    Patent number: 8846625
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 30, 2014
    Assignee: 1149336 Ontario Inc.
    Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
  • METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE
    Publication number: 20140213518
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Application
    Filed: November 5, 2013
    Publication date: July 31, 2014
    Applicant: 1149336 Ontario Inc.
    Inventor: Daniel J. Drucker
  • Methods of Regulating Glucose Metabolism, and Reagents Related Thereto
    Publication number: 20140178472
    Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
    Type: Application
    Filed: July 25, 2013
    Publication date: June 26, 2014
    Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
  • Methods of enhancing functioning of the large intestine
    Patent number: 8603976
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 10, 2013
    Assignee: 1149336 Ontario, Inc.
    Inventor: Daniel J. Drucker
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent number: 8513190
    Abstract: The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: August 20, 2013
    Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
  • GLUCAGON-LIKE PEPTIDE-2 ANALOGS
    Publication number: 20130203673
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Application
    Filed: March 11, 2013
    Publication date: August 8, 2013
    Applicants: 1149336 Ontario, Inc., NPS Pharmaceuticals, Inc.
    Inventors: NPS Pharmaceuticals, Inc., 1149336 Ontario, Inc.
  • METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE
    Publication number: 20120328527
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Application
    Filed: August 30, 2012
    Publication date: December 27, 2012
    Applicant: 1149336 Ontario Inc.
    Inventor: Daniel J. Drucker
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent number: 8318669
    Abstract: The present invention provides methods for modification and regulation of glucagon-like peptide 1 (GLP-1) metabolism by administering therapeutically effective amounts of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to inhibit DPIV proteolysis of GLP-1 but not sufficient to suppress the immune system of the animal.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: November 27, 2012
    Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
  • Methods of enhancing functioning of the large intestine
    Patent number: 8278273
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: October 2, 2012
    Assignee: 1149336 Ontario, Inc.
    Inventor: Daniel J. Drucker
  • Method of Regulating Glucose Metabolism, and Reagents Related Thereto
    Publication number: 20120165252
    Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
    Type: Application
    Filed: November 16, 2011
    Publication date: June 28, 2012
    Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
  • METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE
    Publication number: 20110275568
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Application
    Filed: May 6, 2011
    Publication date: November 10, 2011
    Applicant: 1149336 Ontario Inc.
    Inventor: Daniel J. Drucker
  • GLUCAGON-LIKE PEPTIDE-2 AND ITS THERAPEUTIC USE
    Publication number: 20110223108
    Abstract: Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described.
    Type: Application
    Filed: December 22, 2010
    Publication date: September 15, 2011
    Applicant: 1149336 Ontario, Inc.
    Inventor: Daniel J. Drucker
  • Method of Regulating Glucose Metabolism, and Reagents Related Thereto
    Publication number: 20110172149
    Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
    Type: Application
    Filed: November 9, 2010
    Publication date: July 14, 2011
    Applicants: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
  • Methods of enhancing functioning of the large intestine
    Patent number: 7960344
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: June 14, 2011
    Assignee: 1149336 Ontario, Inc.
    Inventor: Daniel J. Drucker
  • Enhancement of GLP-2 activity of suppressing appetite
    Patent number: 7862824
    Abstract: The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: January 4, 2011
    Assignee: 1149336 Ontario, Inc.
    Inventors: Daniel J. Drucker, Julie Ann Louise Lovshin
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent number: 7829530
    Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: November 9, 2010
    Assignees: Trustees of Tufts College, New England Medical Center Hospitals, 1149336 Ontario, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
  • METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE
    Publication number: 20100119453
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Application
    Filed: October 16, 2009
    Publication date: May 13, 2010
    Applicant: 1149336 Ontario Inc.
    Inventor: Daniel J. Drucker
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent number: 7459428
    Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: December 2, 2008
    Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.
    Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker